GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Total Receivables

CG Oncology (CG Oncology) Total Receivables : $0.15 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Total Receivables?

CG Oncology's Total Receivables for the quarter that ended in Mar. 2024 was $0.15 Mil.


CG Oncology Total Receivables Historical Data

The historical data trend for CG Oncology's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Total Receivables Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
- 0.30 0.09

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial 0.30 - - 0.09 0.15

CG Oncology Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


CG Oncology Total Receivables Related Terms

Thank you for viewing the detailed overview of CG Oncology's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


CG Oncology (CG Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines